Therefore, Chesnokov et al. proposed a novel combination therapy of RCM-1 and venetoclax to overcome venetoclax resistance and disrupt the FOXM1-AKT feedback loop in AML [57]. Here, FOXM1 is linked to acute myeloid leukemia.